Trial Profile
A dose-ranging study of bolus-only Desirudin in patients undergoing PCI
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2014
Price :
$35
*
At a glance
- Drugs Desirudin (Primary) ; Heparin
- Indications Embolism and thrombosis; Unstable angina pectoris
- Focus Pharmacodynamics
- Sponsors Canyon Pharmaceuticals
- 05 Nov 2010 New trial record.